News
NLTX
0.9997
-3.88%
-0.0403
Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating
MT Newswires · 05/31 05:25
Neoleukin Therapeutics Announces First Patient Treated In Combination Arm Of Phase 1 Trial Evaluating NL-201 In Combination With KEYTRUDA (pembrolizumab)
eoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of
Benzinga · 05/16 12:06
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first pati...
GlobeNewswire · 05/16 12:00
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
--Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating
MT Newswires · 05/10 14:22
BRIEF-Neoleukin Therapeutics Files For Offering Of 15.3 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
reuters.com · 05/09 21:27
Neoleukin Therapeutics GAAP EPS of -$0.28 beats by $0.02
Neoleukin Therapeutics press release (NASDAQ:NLTX): Q1 GAAP EPS of -$0.28 beats by $0.02. “During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of
Seekingalpha · 05/09 21:19
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D...
GlobeNewswire · 05/05 12:00
Stocks That Hit 52-Week Lows On Monday
    On Monday, 466 companies hit new 52-week lows.
Benzinga · 04/18 15:40
Neoleukin announces preclinical data for immunotherapy candidate NL-201, shares fall
Shares of Neoleukin Therapeutics (NASDAQ:NLTX) have lost 10.6% in morning trade on Wednesday, despite the company announcing presentation of preclinical data for its immunotherapy candidate NL-201 that highlighted its potential to
Seekingalpha · 04/13 15:06
Neoleukin Therapeutics Says NL-201 Preclinical Data Show Potential to Treat Hematologic Cancers; Shares Fall
MT Newswires · 04/13 12:18
Neoleukin Therapeutics Reports Will Present At Canaccord's Horizons In Oncology Conference Thursday, Apr. 14, 2022 At 12 p.m. EDT
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that
Benzinga · 04/07 12:16
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M...
GlobeNewswire · 04/07 12:00
BRIEF-Neoleukin Therapeutics Announces Appointment Of Donna Cochener As General Counsel
reuters.com · 03/15 12:17
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
SEATTLE, March 15, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Donna ...
GlobeNewswire · 03/15 12:00
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations at th...
GlobeNewswire · 03/08 21:01
--Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating
MT Newswires · 03/02 12:04
Recap: Neoleukin Therapeutics Q4 Earnings
Neoleukin Therapeutics (NASDAQ:NLTX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 03/01 21:32
Notable earnings after Tuesday's close
AIV, AMC, ARLO, ATEC, AVID, BGFV, BGS, BNFT, BNGO, BODY, BROS, CARA, CCXI, CDLX, CELH, CERT, CLPT, CRM, CTMX, DMTK, DOMO, EC, FSLR, GO, GRBK, GRWG, HCAT, HPE, HRZN, HYFM,
Seekingalpha · 02/28 22:35
More
Webull provides a variety of real-time NLTX stock news. You can receive the latest news about Neoleukin Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NLTX
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Its primary areas of focus are oncology, inflammation and autoimmunity. Its technology, Neoleukin platform, uses a set of advanced computational algorithms and methods to design functional de novo proteins. Neoleukin’s lead program, NL-201, is a computationally designed de novo protein therapeutic. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities. NL-201 has also shown promise in combination with allogenic cell therapy to expand and maintain populations of transplanted CAR-T and NK cells.